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Summary The aromatase inhibitor, 'pyridoglutethimide' (PyG), has been shown previously to suppress serum
oestrogen levels in postmenopausal breast cancer patients and to achieve clinical responses at a dose of 500 mg
twice daily (b.d.). This report gives the results of a detailed pharmacokinetic and endocrine study of PyG in
ten patients. Four doses were tested at intervals of 2 weeks in the following order: 200 mg b.d., 400 mg b.d.,
800 mg b.d., 1200 mg b.d. Concentration-time profiles of serum levels of PyG were curvilinear in all patients
probably reflecting a saturation of metabolic enzymes. During repeat-dosing metabolism was enhanced
approximately 2-fold. Plasma levels of oestradiol were significantly suppressed by the lowest dose of PyG.
Although higher doses appeared to achieve greater suppression this was not statistically significant in this
small group of patients. There were no significant effects at any dose on the serum levels of cortisol,
aldosterone, luteinising hormone, follicle stimulating hormone, prolactin, sex hormone binding globulin or
thyroid stimulating hormone. There was a dose-related increase in 17a-hydroxyprogesterone levels and a
dose-related decrease in levels ofdehydroepiandrosterone sulphate (DHAS). The androgens DHA, testosterone
and androstenedione also were significantly suppressed with at least one of the doses of PyG. Synacthen tests
did not support these changes being a result of inhibition of 17,20 lyase. It is possible that they are due to
enhanced clearance of DHAS. Two patients experienced no toxicity throughout the study, whilst a total of
four patients were withdrawn because of side-effects: one at 400 mg b.d., two at 800 mg b.d., and one at
1200 mg b.d. The most frequent side-effects were nausea and lethargy. One patient showed an objective
response to treatment.
The inhibition of peripheral aromatase activity has been
established as an effective means of treatment of postmeno-
pausal breast cancer patients by the use ofaminoglutethimide
and more recently, 4-hydroxyandrostenedione, a steroidal
compound (Santen et al., 1978; Harris et al., 1983a; Stuart-
Harris et al., 1985; Coombes et al., 1984). Aminoglutethimide
has significant clinical side effects and also inhibits 20, 22-
desmolase, 1ll1-hydroxylase and 18-hydroxylase, which have
led to its use with concommitant glucocorticoid therapy
(Santen et al., 1981). A number of non-steroidal compounds
are under development with the expectation of achieving a
more selective inhibition of aromatase than that with amino-
glutethimide. Clinical studies have been reported with two
such compounds.
The first of these, CGS 16949A, is a tetrahydroimidazo-
pyridine derivative which has been found to be clinically and
endocrinologically effective at a much lower dose than
aminoglutethimide (Stein et al., 1990; Dowsett et al., 1990;
Santen et al., 1989). However, some studies have indicated
that aldosterone levels are suppressed at therapeutic doses of
the drug (Dowsett et al., 1990). Associated changes in elec-
trolyte balance were found in the patients although the
clinical significance of this is probably small (Stein et al.,
1990).
The other compound, 3-ethyl-3-(4-pyridyl)piperidine-2,6-
dione (PyG) is an analogue of aminoglutethimide which has
been commonly known by the name ofpyridoglutethimide. It
has recently been registered under the internationally accept-
ed name of rogletimide. It has been found to lack the effects
of aminoglutethimide on cholesterol side chain cleavage but
its inhibitory potency on aromatase in vitro is similar to that
of aminoglutethimide (Santen et al., 1981; Foster et al.,
1985). In a preliminary clinical study the pharmacokinetics of
PyG were found to be non-linear and the drug appeared to
induce its own metabolism (Haynes et al., 1991). Plasma
oestradiol levels were suppressed to 31.1 ± 6.3% (mean ±
s.e.m.) by a 500 mg dose taken twice daily (b.d.). The current
study was undertaken to find if PyG had any dose-related
toxicity and to characterize (i) the dose-related pharmaco-
kinetics and bioavailability of PyG, (ii) its dose-related effect
on circulating oestrogen levels and (iii) the specificity of the
oestrogen suppression. In addition any evidence of clinical
efficacy was noted.
Materials and methods
Patients
Ten patients were recruited. Eligibility criteria demanded that
they had histologically or cytologically proven advanced
metastatic breast cancer and were postmenopausal (LMP>2
years and FSH> 20 IU 1-). Previous endocrine treatment
must have stopped at least 4 weeks previously. Oestrogen
receptor status was either positive (n = 5) or unknown. The
protocol was approved by the Ethical Committees of the
Royal Marsden and St George's Hospital. All patients gave
informed consent prior to entry. The demnographic data are
given in Table I. No patients were receiving drugs known to
alter the metabolic clearance of other pharmacologic agents.
Study design
The protocol was designed to allow detailed endocrine and
pharmacokinetic studies in a small number of patients. The
basic design was to treat each patient with 200,.400, 800 and
1200 mg PyG b.d. (twice daily) for periods of 2 weeks on
each dose without a wash-out period between doses. The day
on which the first 200 mg b.d. dosage was given, was desig-
nated day 0, such that increases in dosage occurred on days
14, 28 and 42.
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Table I Clinical details ofpatients treated with PyG
Sites of Response at Duration
Patient Age Previous treatment disease 10-12 w Toxicity (lowest dose) (withdrawal dose)
1 62 AG(adj),T,CGS In NA depression, lethargy (800) 5 w (800)
2 62 nil In NC nil 7m
3 54 OVx lo NC flushes (800), depression (1200) 7 m
4 58 chemo(adj),T(adj) bo NA nausea (400), lethargy (800) 7 w (1200)
5 72 T lo,bo NA nausea, vomiting, lethargy (400) 3 w (400)
6 54 OVx lo,bo,vis NC/PR lethargy, flushes (800) 6 m
7 55 T,chemo lo,bo,vis PR nil 7 m
8 68 T bo NA lethargy (800) 6w (800)
9 63 40HA lo,bo,vis PD flushes (1200) 3 m
10 72 T In PD nausea, lethargy (400) 3 m
Abbreviations: AG, aminoglutethimide; T, tamoxifen; CGS, CGS 16949A; OVx,ovariectomy; chemo,chemotherapy;40HA,
4-hydroxyandrostenedione; adj, adjuvant; In, lymph nodes; lo, local; bo, bone; vis,visceral; NA, non-assessable; NC, nochange;
PR, partial response; PD, progressive disease.
Pharmacokinetic protocol
To compare the pharmacokinetics of orally and intraven-
ously administered compound, single doses of PyG were
given by each route on days -10 and -3. The dose adminis-
tered was 400 and 800 mg to patients 1 to 5 and 6 to 8,
respectively. The order of the initial treatment with oral or
intravenous PyG was randomised for each dose. Patients 9
and 10 received only a single oral dose of 1200mg on day
-10. To compare the pharmacokinetics of these single doses
with those on repeat administration patients 1 to 5 received a
single oral dose of 400 mg on day 28 with no treatment on
day 29, patients 6 to 8 received a single oral dose of 800 mg
on day 42 with no treatment on day 43 and patients 9 and 10
received a single 1200 mg dose on day 56 with no treatment
on day 57. The patients fasted overnight before each of the
days on which the single doses were administered (at 09.00).
Heparinised blood samples were collected for drug analysis
immediately before and at the following time points after
single dose administration: 30 min, 1, 2, 4, 6, 8, 12, 15, 24,
28, 32, 36 and 48 h. The separated plasma was stored at
-20°C until analysis.
Drug analyses
Plasma concentrations of PyG and its principal metabolite,
the N-oxide (NO-PyG) were measured by reverse-phase
HPLC with UV detection at 254 nm according to previously
published methodology (Haynes et al., 1991).
Endocrine protocol
Baseline blood samples were taken on days -11, -10 and -3 at
09.00. Further blood samples for endocrine analysis were
obtained at 09.00 on day 7 and at 7 day intervals thereafter
until day 56 inclusive. The samples were drawn immediately
prior to the morning dose being given. On days -11, 27 and
55 (i.e. pretreatment and on 400 mg and 1200 mg b.d.),
250 mg intramuscular injections of synacthen were given
immediately after the morning dose of the drug. Blood sam-
ples were taken 30 and 60 min after injection. The endocrine
sample taken immediately before the dose of PyG was also
used as the baseline sample for the synacthen test. Samples
were allowed to clot and the serum was separated and stored
at - 20C until analysis.
Endocrine analyses
The following analytes were measured in serum samples by
immunoassays according to previously published methodo-
logy: oestradiol (Dowsett et al., 1987), oestrone (Harris et al.,
1983b), androstenedione (Dowsett et al., 1984), testosterone,
dehydroepiandrosterone sulphate (DHA-S) and 17a-hydroxy-
progesterone (170HP) (Harris et al., 1982), aldosterone
(Dowsett et al., 1990), LH and FSH (Ferguson et al., 1982),
prolactin (Harris et al., 1983c) and SHBG (Dowsett et al.,
1986). Cortisol was measured using the DPC coat-a-count
kit. The only endogenous steroids which cross-reacted by
> 1% were corticosterone (1.4%) and 1 1-deoxycorticoste-
rone (1.5%). DHA was measured using the tritiated-ligand
extraction radioimmunoassay kit from RSL. Cross-reactions
were noted as follows: androstenedione (0.3%) and all others
<0.01%). TSH was measured using the Biogenesis-kit.
There were no measurable cross-reactions with other peptides
hormones. The within- and between-assay coefficients of vari-
ation were <7% and < 12% for each of these three assays.
Clinical assessments
Full staging was carried out on day 0 and between days 70
and 84. This included full clinical examination, limited radio-
logical skeletal survey, chest X-ray and CT scanning of the
liver when indicated and routine biochemical and haemato-
logical investigations. Liver and bone scans were conducted
as indicated by the clinical condition. Additional clinical
examinations were made at weekly intervals for the first 8
weeks. Treatment with PyG was continued after 8 weeks at a
dose of 400 mg b.d. until there was objective evidence of
progressive disease. Standard toxicology charts were com-
pleted at each clinical examination. Response was assessed
according to standard UICC criteria.
Statistical analyses
Pretreatment values were calculated as the mean of the levels
on days -11, -10 and -3. All comparisons, other than for
oestradiol were performed by calculating mean ± 95% con-
fidence intervals from pretreatment. Thus statistical com-
parisons are made only with pretreatment values and are
considered as significant if the 95% confidence interval does
not include zero. For oestradiol a repeated-measures design
analysis of variance was conducted. In no case was there
sufficient divergence from a normal distribution to merit
log-transformation of the data.
Results
Pharmacokinetics
The concentration-time profiles ofPyG were curvilinear in all
patients during both the single- and repeat-dose phases of the
study. A typical plot for a patient on the 400mg dose is
shown in Figure 1. The single oral and intravenous doses
give virtually superimposable profiles for both PyG and its
N-oxide metabolite (not shown). Calculation of the bioavail-
ability gave mean (± s.d.) values of 95.7 + 9.8% and 99.2 +
6.2% at 400 mg (n = 5) and 800 mg (n = 3) respectively. The
data were fitted to the integrated Michaelis-Menten equation
and the estimates of Co, Km and Vmax following oral
dosing are given in Table II. The estimates for these para-
meters were excellent after single dosing as indicated by the
small standard errors. On repeated dosing the estimates werePYRIDOGLUTETHIMIDE IN BREAST CANCER 889
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Figure 1 Plasma concentration-time profiles of PyG in one
patient following administration of a 400 mg dose after a single
dosing (oral, 0; intravenous, 0) and during repeated dosing
(oral, A).
less precise probably because the more rapid decline in PyG
levels resulted in fewer data points to define the curve. There
was no significant change in Co but increases in both Km
and Vmax were observed on repeated dosing in comparison
with the single dose. The area under the curve (AUC) obtain-
ed following single dosing was reduced by a mean (± s.d.)
56.7 ± 15.5% in the four patients on 400mg, by 52.6 and
37.7% in the two patients on 800 mg and by 56.5% in the
patient on 1200 mg. The overall mean reduction in AUC was
53.3 ± 13.1%.
There was accumulation of NO-PyG on repeated dosing
although its terminal half-life did not change compared with
the single dose situation (3.6 ± 0.4 and 3.9 ± 0.3 h, respec-
tively). The AUC of NO-PyG increased by greater than 40%
in all patients on repeated dosing (Table II). Moreover, the
ratios of the AUC's of NO-PyG to PyG increased 2-6-fold
in all patients on repeated dosing.
C0
0
-o
K
C
a)
10
00
C)
Cd
0.
0
a)
C
a.)
0
24
0
Endocrine results
The serum oestrogen levels in patient 8 were far above the
normal postmenopausal range before treatment by PyG, des-
pite her being unequivocally postmenopausal and of normal
weight, and are therefore presented separately in Table III.
There appeared to be a dose-related fall in serum oestradiol
and oestrone levels in this patient. She was withdrawn from
therapy because of toxicity at 800mg b.d., and she died
shortly afterwards, before any explanation for her abnormal
oestrogen levels could be established.
The suppression of serum oestradiol levels in the remaining
nine patients is shown in Figure 2 as a function ofdose, both
as the absolute concentration and as a percentage of the
baseline level. There was a significant fall in oestradiol levels
even at the lowest dose of 200 mg b.d. (P = 0.0001).
Although there appeared to be greater suppression at the two
highest doses that was not statistically significant. Mean
pretreatment oestrone levels were 58 ± 14 (s.e.m.) pmol 1-l.
Levels were undetectable (<30 pmolI1) in 7/9 at 200mg
b.d., 8/9 at 400 mgb.d., 6/7 at 800 mg b.d., and 5/6 at
1200 mg b.d.
The on-treatment data on other endocrine parameters are
presented in Figure 3, 4 and 5 as the mean change from
baseline ± 95% confidence interval, such that points at which
the error bar does not intersect the line of no change are
statistically significant from pretreatment at the 5% level.
Mean baseline values for each analyte are given in Table IV.
There were no significant changes in the serum levels of
LH, FSH, prolactin, SHBG or TSH during treatment at any
of the dose levels of PyG (Figure 3). Similarly there were no
significant alterations of cortisol and aldosterone levels.
However, there was a dose-related increase in the serum
levels of 170HP which was statistically significant at the two
highest dose levels (Figure 4). In contrast the serum levels of
DHA, DHAS, androstenedione and testosterone all showed a
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Table III Suppression of serum oestrogen levels by PyG in patient 8
200mg 400mg 800 mg
Units Baseline b.d. b.d. b.d.
Oestrone pmol 1- 320 177 67 55
% of baseline 100 55 21 17
Oestradiol pmol l- 273 243 187 137
% of baseline 100 89 69 50
2
I
-J
2
-r I
Un
a
-J
0
E
-a -o
en a)
0
20 -
15 -
10-
5-
n = 9 9 9
PRE 200 400
8 6
800 1200
10- LH
5-
0~~~~~~~~~
-5
-10
n = 10 9 8O 5
-15P 2 4 1
PRE 200 400 800 1200
15 FSH
10
5
0
-5- I
10n= 10 9 8 5 P15R 00
PRE 200 400 800 1200
- 1000 Prolactin
E 500
'r 0.
0 n =10 9 81 5
X -500
-4 PRE 200 400 800 1200
-0
-5
Ch U1)
0
b
100 -
80 -
60
40-
20-
O-
2
0
E
(9
I
C,
n =9 9 8 6
PRE 200 400
Dose (mg bd)
Figure 2 Suppression of serum oestradiol levels by PyG. The
results are expressed as a, absolute concentrations and b, percen-
tage of baseline.
significant fall for at least one dose level. There was some
indication that this was dose-related, particularly with
DHAS. There was also a dose-related increase in the ratio of
170HP/androstenedione which was significant for each dose
above 200 mg b.d. but there was no significant change in the
170HP/cortisol ratio (Figure 5).
Synacthen tests were performed before treatment with PyG
and at the doses of400 and 1200 mg b.d. The serum levels of
cortisol, aldosterone, 170HP and androstenedione before
and after synacthen are shown in Figures 6 and 7. It can be
seen in Figure 6 that there were synacthen-induced increases
in all four steroids before and during treatment with PyG.
The mean responses during treatment with PyG were greater
than before treatment but this was statistically significant
only for 170HP at the dose of 400 mg b.d. (Figure 7). There
were no significant changes during PyG treatment in the
ratios of 170HP/androstenedione and 170HP/cortisol after
synacthen stimulation (results not shown).
Clinical results
The clinical results are summarised in Table I. One of the
patients showed an objective partial response to treatment.
Some toxicity was noted in 8/10 patients. This necessitated
withdrawal from the study of four patients. However, no
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Figure 3 Effect of PyG on serum levels of LH, FSH, prolactin,
SHBG and TSH. The figures show for each dose the mean
change from mean baseline value±95% confidence interval.
toxicity was noted at 200mgb.d. and only three patients
exhibited side-effects at 400 mg b.d., one of which was with-
drawn. Two of the withdrawals were made at 800 mg b.d.
and one at 1200 mg b.d.
Discussion
There are several inhibitors of aromatasae which are in the
early phases of clinical development. The selection of the
optimal drug for the future treatment of breast cancer
patients will be determined by comparisons ofclinical efficacy
and toxicity. However, pharmacological effectiveness and
selectivity of the aromatase blockade contribute to the
efficacy and toxicity, respectively and detailed pharmaco-
logical studies can be a useful prelude to large scale clinical
trials. In the current study it was notable that marked sup-
pression of oestradiol levels occurred at 200 mg b.d. with no
significant further suppression at higher doses. The measure-
ments of oestrone and oestradiol were made 7 and 14 days
after a change of dose. Oestrone sulphate contributes to the
plasma pool of oestrone and oestradiol, and has a long
half-life, such that oestrone and oestradiol levels may not
have been entirely stable at these time points. However, there
was no evidence of lower oestrone or oestradiol levels in the
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Figure 4 Effect of PyG on serum levels of 170HP, DHA,
DHAS, androstenedione, testosterone, cortisol and aldosterone.
The figures show for each dose the mean change from mean
baseline value±95% confidence interval.
14 day samples compared with those at 7 days which sug-
gests that the effects of any continued change in oestrone
sulphate levels would have little impact on the results of the
study. With such a small number ofpatients it is not possible
to select the optimal dose for therapeutic clinical trial
although it seems unlikely that a dose of 1200b.d. will be
Figure 5 Effect of PyG on the ratios of serum levels of 170HP/
androstenedione and of 170HP/cortisol. The figures show for
each dose the mean change from mean baseline value ±95%
confidence interval.
necessary. Limitations of assay sensitivity also diminish the
ability of such studies to distinguish between doses. Further
investigation of larger numbers of patients together with the
measurement by isotopic kinetic analysis of the degree of
inhibition of peripheral aromatase in vivo by different doses
of PyG are required to select a maximally effective dose.
The data on baseline and synacthen-stimulated serum
levels of cortisol and aldosterone and of 170HP/cortisol
ratios indicated that there was no significant inhibition of
11p-, 21- or 18-hydroxylases even at the highest dose of PyG
used. This is in contrast to the data on aminoglutethimide
which, when used without glucocorticoids, significantly inhi-
bits 1lp-hydroxylase and 18-hydroxylase at therapeutic doses
(Santen et al., 1981) and causes increases in the levels of the
androgenic precursors of aromatase (Harris et al., 1983a;
Stuart-Harris et al., 1985). We have also found that CGS
16949A causes a significant suppression of aldosterone levels
at therapeutic doses (1 mg and 2 mg b.d.) (Dowsett et al.,
1990) and Santen et al. (1989) have noted increases in
170HP and androstenedione levels with this drug.
The suppression of androgen levels by PyG was not antici-
pated. The small dose-related increase in 170HP levels sug-
gested that this might have been due to inhibition of 17,20
lyase, the enzyme converting 170HP and 17hydroxypreg-
nenolone to androstenedione and DHA, respectively and this
is supported by the increases noted in the 170HP/andro-
stenedione ratio. 17,20 Lyase activity is accomodated within
the same enzyme complex at 170c-hydroxylase. Any inhibiton
of that activity would be expected to result in reduced cor-
tisol feedback and an increase in adrenal drive which might
compensate for an incomplete block. However, the results
from the synacthen-test for androstenedione do not support
the postulated inhibition of 17,20 lyase. Such inhibition
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Table IV Mean (±s.e.m.) pretreatment serum hormone levels
Oestradiol* 20.5 2.5 pmol I l
Oestrone* 58.3 1.3 pmol 1-'
LH 34.3 3.3 IU 1-'
FSH 37.1 2.0 IU 1-'
Prolactin 215 ±78 mIU 1'
SHBG 88.2 14.0 nmol 1-
TSH 2.5+0.5 IU 1-'
170HP 1.0±0.1 nmol 1'
DHA 2.9 0.5 nmol 1'
DHAS 1.5 0.3 ltmol 1'
Androstenedione 4.0 0.6 nmol 1'
Testosterone 1.2±0.1 nmol 1'
Cortisol 491 ±56 nmol 1-'
Aldosterone 493 ± 105 pmol 1'
*Excludes patient 8.
should lead to a decreased response of androstenedione levels
to synacthen stimulation, whilst the observed results showed
a marginally increased response and there was not change
during PyG treatment in the 170HP/androstenedione ratio
subsequent to synacthen stimulation. In addition, our studies
of PyG in guinea pig adrenal cell incubates and in enzyme
preparations from rat testes showed no evidence of inhibition
of 17,20 lyase activity (results not shown).
It is possible that the explanation could lie in an increased
metabolic clearance of DHAS. Haning and colleagues (1989)
have recently demonstrated that hydrolysis of DHAS signi-
ficantly contributes to the overall production of DHA and
androstenedione. The related drug aminoglutethimide has
been noted to enhance the clearance of oestrone sulphate
(Lonning et al., 1989). There is also an unexplained minor
fall in DHAS levels in patients on aminoglutethimide without
replacement glucocorticoid which is coincident with increases
in unconjugated androgens (due to the inhibition of 11p-
hydroxylase) (Stuart Harris et al., 1985).
Whatever the mechanism of this fall, it is theorectically
advantageous to the drug in terms of the overall aim of
supressing oestrogen levels, since androstenedione is the main
substrate for aromatase. We have not measured androstene-
diol in this study but it seems likely that the levels of this
would fall in parallel with the other adrenal androgens. It is
widely accepted that androstenediol has weak oestrogenic
activity. Therefore suppression of this steroid would also be
expected to decrease overall oestrogenic stimulation. It is also
possible that PyG might be useful therapeutically in the
suppression of adrenal androgen synthesis. It may therefore
be helpful in combination with or subsequent to castration in
prostatic cancer patients.
The lack of change in the levels of LH, FSH and SHBG
indicate that the drug has no significant inherent oestrogenic
or androgenic activity. That these parameters do not change
in response to the fall in oestrogen levels is probably due to
their lack of sensitivity to such a quantitatively small perfur-
bation. The absence of a rise in TSH levels indicates that
PyG lacks the inhibitory effect that aminoglutethimide has
on thyroxine synthesis (Santen et al., 1977).
The excellent bioavailability of PyG found in this study
compares well with that of aminoglutethimide (Lonning et
al., 1985), and demonstrates the effectiveness of oral dosing.
PyG has previously been shown to exhibit non-linear phar-
macokinetics after a single oral dose of 1000 mg (Haynes et
al., 1991). This was attributed to saturation of the formation
of NO-PyG. In this study PyG was found to possess non-
linear kinetics even at the dose of 400mg. This would be
expected as the concentration at which 50% saturation of
PyG elimination occurs (the Km) was found to be in the
range 0.83-2.15pgml-' and the peak plasma concentrations
occurring after administration of the 400 mg dose were much
higher that this. Indeed, we have observed non-linearities in
the pharmacokinetics of PyG after doses as low as 50 mg
(unpublished data). PyG induced its own metabolism at all
three dose levels investigated such that the AUC of the drug
was reduced by an overall mean of over 50%. This pheno-
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Figure 7 Response of serum levels of cortisol aldosterone,
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treatment with PyG. The figures represent the mean difference in
the increment during treatment with PyG from the increment
before treatment, ±95% confidence interval.
menon has been observed previously in patients receiving
1,000 mg o.d. for 5 days and was attributed to induction of
the N-oxidation process (Haynes et al., 1991). This would
appear to be borne out in the present study in that AUC of
NO-PyG increased in all patients after repeated dosing.
There was only one objective responder to PyG in this
study, but we have previously reported that remissions occur-
red in an earlier study (Haynes et al., 1991) and the time of
scoring the clinical responses in this study (70-84 days) is a
little early to detect all partial regressions. The response rate
to other second line endocrine therapy in breast cancer is
about 25%. The occurrence of one responder from a group
of ten patients is within the 95% confidence limits of a 25%
response rate.
Side-effects were clearly dose-related such that all patients
tolerated the lowest dose and only one patient had to with-
draw on 400mgb.d. A further two patients were withdrawn
at 800 mg b.d. and a total of40% ofpatients had withdrawn
before the end of the study on 1200 mg b.d. However, these
toxic effects at high doses may be academic since the
measurements of oestrogenic suppression indicated that the
drug might well be effective at doses below 800 mg b.d. The
side-effects noted may be considered to be reminiscent of
those seen with aminoglutethimide (Santen et al., 1981), how-
ever no other specific neurologic side-effects and no ataxia
were observed. This is consistent with comparative animal
toxicology studies which revealed no sedative or ataxic effect
of PyG at doses higher than those at which severe effects
were found with aminoglutethimide (Foster et al., 1985).
In conclusion, it may be said that PyG is an interesting
new aromatase inhibitor which is an effective oestrogen sup-
pressant at a dose of 200 mg b.d. It lacks the detrimental
endocrine side-effects of aminoglutethimide and CGS 16949A
on other enzyme systems. Indeed, its suppression of andro-
gen levels, although currently unexplained, leads to the
exciting possibilities that the overall suppression of oestrogen
synthesis may be enhanced through this effect and that the
drug may be useful in the treatment of prostatic cancer. The
dose-related side-effects indicate that a dose of less than
800 mg b.d. is to be preferred.
These studies were partially funded by a grant from the Cancer
Research Campaign. Additional funds were provided by US Bio-
science, Blue Bell, PA.
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